But I think that the--
the key point here
is beer category
remains vibrant,
is growing globally, gaining
share of throat
and is projected for all sources,
IFWR, Euromonitor
to continue
to grow
globally,
volumes and gaining
share of throat.
At this stage,
I think that it's too early
to assess any overlap
or change in behavior
in relevant consumer groups.
You see that the
penetration
of these drugs
is still very small,
and that is like
a relatively wide range
of points of view
on where this is going
with very limited data.
I think that for us,
we don't see any impact
so far in the business.
Our portfolio, as you know,
have several different options
for socialization
and consumers understand
that.
And the big distinction
because we are not in the
indulgence business right,
so you see a lot of the conversations
around sweet
and more things
that are related to indulgence,
which is not the case
of our portfolio.
On top of that,
we have like an incredible
range of offers
with low calorie,
low carb,
non-alcohol,
think about Michelob ULTRA...
Michel Doukeris, ABInBev CEO, responds during the Q3 2023 earnings call.
Roman Ryan 